Three additional autoimmune diseases, PV, ITP, CSU as well as two inflammatory immune-mediated diseases, GVHD and asthma, were diseases where two or fewer BTK inhibitors in clinical trials were tested. This evidence concerns the gene BTK and acquired polycythemia vera.